Feature|Videos|July 29, 2024
Enzene Expands Into the US and Will Provide State-of-the-Art Fully Connected Continuous Manufacturing Services to Pharma and Biotech Companies
Author(s)Enzene Biosciences Ltd.
Key Takeaways
Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd., describes the rationale for expanding its services, including its patented EnzeneX™ continuous manufacturing technology platform, to emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.
Watch the video and learn more:
- What distinguishes EnzeneX™ technology from other existing continuous processing manufacturing methods.
- Types of customers that can benefit from EnzeneX™ technology and other Enzene Biosciences Ltd. services.
- Updates pertaining to the launch of Enzene's first US-based manufacturing plant.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
